Millipore Sigma Vibrant Logo

574625 Suramin, Sodium Salt - CAS 129-46-4 - Calbiochem

概述

Replacement Information

重要规格表

CAS #Empirical Formula
129-46-4C₅₁H₃₄N₆O₂₃S₆ . 6Na

价格及供货情况

产品目录编号 库存情况包装 数量 / 包装 价格 数量
574625-50MGCN
正在查询供货情况......
目前缺货
目前缺货
有货 
停产
少量现货
供货情况有待确认
    其余:另行通知
      其余:另行通知
      另行通知
      联系客户服务
      Contact Customer Service

      塑胶安瓿;塑胶针药瓶 50 mg
      正在检索价格......
      无法检索价格。
      最小订购数量为倍数
      Maximum Quantity is
      以订单确认为准 更多信息
      您节约了 ()。
       
      Request Pricing
      Description
      OverviewA reversible and competitive inhibitor of protein tyrosine phosphatases. An anti-neoplastic, anti-angiogenic agent that uncouples G-proteins from receptors presumably by blocking their interaction with intracellular receptor domains. Inhibits GDP-GTP exchange, the rate limiting step in the activation of Gα-subunits. A competitive inhibitor of reverse transcriptase. Reported to inhibit topoisomerases I and II. Inhibits Ca2+-ATPase in sarcoplasmic reticulum membranes. Also inhibits the cell-surface binding of various growth factors, including EGF, PDGF, and TGF-β. An inhibitor of phospholipase D (IC50 = 15 µM). Reported to interact with ATP-binding enzymes and P2-purinergic receptors. An effective inhibitor of angiogenesis in the calmodulin assay when given in combination with angiostatic steroids.
      Catalogue Number574625
      Brand Family Calbiochem®
      SynonymsPurinergic Receptor P2Y Antagonist I, PTP Inhibitor VI, P2Y Antagonist I
      References
      ReferencesMeyers, M.O., et al. 2000. J. Surg. Res. 91, 130.
      Hohenegger, M., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 346.
      Waldhoer, M., et al. 1998. Mol. Pharmacol. 53, 808.
      Zhang, Y.L., et al. 1998. J. Biol. Chem. 273, 12281.
      Hohenegger, M., et al. 1996. Mol. Pharmacol. 50, 1443.
      Emmick, J.J., et al. 1994. J. Pharmacol. Exp. Ther. 269, 717.
      Denhertog, A., et al. 1992. J. Physiol. 454, 591.
      Nakajima, M., et al. 1991. J. Biol. Chem. 266, 9661.
      Wilks, J.W., et al. 1991. Int. J. Radiat. Biol. 60, 73.
      Huang, R.C., et al. 1990. Mol. Pharmacol. 37, 304.
      Kopp, R. and Pfeiffer, A. 1990. Cancer Res. 50, 6490.
      Product Information
      CAS number129-46-4
      ATP CompetitiveN
      FormWhite to beige to peach crystalline solid
      Hill FormulaC₅₁H₃₄N₆O₂₃S₆ . 6Na
      Chemical formulaC₅₁H₃₄N₆O₂₃S₆ . 6Na
      Hygroscopic Hygroscopic
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary Targetprotein tyrosine phosphatases
      Primary Target IC<sub>50</sub>15 µM against phospholipase D
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableN
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      RTECSQM7000000
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      产品目录编号 GTIN
      574625-50MGCN 04055977189636

      Documentation

      Suramin, Sodium Salt - CAS 129-46-4 - Calbiochem MSDS

      职位

      物料安全数据表 (MSDS) 

      Suramin, Sodium Salt - CAS 129-46-4 - Calbiochem 分析证书

      标题批号
      574625

      参考

      参考信息概述
      Meyers, M.O., et al. 2000. J. Surg. Res. 91, 130.
      Hohenegger, M., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 346.
      Waldhoer, M., et al. 1998. Mol. Pharmacol. 53, 808.
      Zhang, Y.L., et al. 1998. J. Biol. Chem. 273, 12281.
      Hohenegger, M., et al. 1996. Mol. Pharmacol. 50, 1443.
      Emmick, J.J., et al. 1994. J. Pharmacol. Exp. Ther. 269, 717.
      Denhertog, A., et al. 1992. J. Physiol. 454, 591.
      Nakajima, M., et al. 1991. J. Biol. Chem. 266, 9661.
      Wilks, J.W., et al. 1991. Int. J. Radiat. Biol. 60, 73.
      Huang, R.C., et al. 1990. Mol. Pharmacol. 37, 304.
      Kopp, R. and Pfeiffer, A. 1990. Cancer Res. 50, 6490.

      数据表

      标题
      SIRTainty™ Class III HDAC Assay
      数据表

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision13-October-2020 JSW
      SynonymsPurinergic Receptor P2Y Antagonist I, PTP Inhibitor VI, P2Y Antagonist I
      DescriptionAn anti-neoplastic, anti-angiogenic agent that uncouples G-proteins from receptors presumably by blocking their interaction with intracellular receptor domains. A competitive inhibitor of reverse transcriptase. Reported to inhibit topoisomerase I and II. Inhibits Ca2+-ATPase in sarcoplasmic reticulum membranes. Also inhibits the cell-surface binding of various growth factors including EGF, PDGF, and TGF-β. An inhibitor of phospholipase D (IC50 = 15 µM). Reported to interact with ATP-binding enzymes and P2-purinergic receptors. An effective inhibitor of angiogenesis in calmodulin assays when given in combination with angiostatic steroids.
      FormWhite to beige to peach crystalline solid
      CAS number129-46-4
      RTECSQM7000000
      Chemical formulaC₅₁H₃₄N₆O₂₃S₆ . 6Na
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityH₂O (5 mg/ml)
      Storage +2°C to +8°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
      Toxicity Standard Handling
      Merck USA index14, 9006
      ReferencesMeyers, M.O., et al. 2000. J. Surg. Res. 91, 130.
      Hohenegger, M., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 346.
      Waldhoer, M., et al. 1998. Mol. Pharmacol. 53, 808.
      Zhang, Y.L., et al. 1998. J. Biol. Chem. 273, 12281.
      Hohenegger, M., et al. 1996. Mol. Pharmacol. 50, 1443.
      Emmick, J.J., et al. 1994. J. Pharmacol. Exp. Ther. 269, 717.
      Denhertog, A., et al. 1992. J. Physiol. 454, 591.
      Nakajima, M., et al. 1991. J. Biol. Chem. 266, 9661.
      Wilks, J.W., et al. 1991. Int. J. Radiat. Biol. 60, 73.
      Huang, R.C., et al. 1990. Mol. Pharmacol. 37, 304.
      Kopp, R. and Pfeiffer, A. 1990. Cancer Res. 50, 6490.